What cholesterol actually is — and what statins take from the body

When cholesterol is pushed too low: brain fog, weakness, and arrhythmia

The current aggressive push — combining statins with PCSK9 inhibitors to drive total cholesterol to 100–150 mg/dL — is being marketed as a cardiovascular ideal. Clinically, this range produces a recognizable symptom cluster in a significant number of patients: cognitive impairment and brain fog, generalized muscle weakness and fatigue, and cardiac arrhythmia. When cholesterol is allowed to rise back toward physiological levels, these symptoms frequently resolve. This is not surprising when you understand what cholesterol does: The brain is 25% cholesterol by weight and synthesizes its own supply independently of serum cholesterol — but statins that cross the blood-brain barrier (lipophilic statins: simvastatin, atorvastatin, lovastatin) do suppress brain cholesterol synthesis. Cholesterol is required for myelin sheath integrity, synaptic vesicle formation, and neurosteroid production. Very low cholesterol is associated with increased risk of depression, cognitive decline, and — in population studies — dementia. Brain fog and memory impairment are among the most commonly reported statin side effects, often normalized or dismissed. Statins inhibit the mevalonate pathway — the same pathway that produces CoQ10. Every muscle cell depends on CoQ10 for mitochondrial energy production. Skeletal muscle weakness, myalgia, and in severe cases rhabdomyolysis (muscle breakdown) are documented statin effects. When total cholesterol is driven to 100–150 mg/dL via combined drug therapy, the physiological substrate for cell membrane repair, hormone synthesis, and energy production is severely depleted. Patients report weakness that clinicians attribute to age, deconditioning, or anxiety. Cardiac cell membranes require cholesterol for structural integrity and for the function of ion channels — particularly sodium and potassium channels — that govern the electrical impulses driving heart rhythm. Extremely low cholesterol impairs membrane fluidity and ion channel function. Statin-associated arrhythmia is documented in the literature and in FDA adverse event reports. The paradox: a drug prescribed to protect the heart can, via CoQ10 depletion and membrane disruption, destabilize the electrical system that keeps it beating regularly. What to ask: If you are on a statin or PCSK9 inhibitor and experiencing brain fog, memory changes, muscle weakness, or new-onset arrhythmia — ask for a total cholesterol number, not just LDL. If your total cholesterol is below 160 mg/dL, consider whether the drug dose is appropriate and what physiological functions may be compromised. These symptoms are not always drug side effects — but they are not always age either. Sunlight and cholesterol: UVB exposure in the skin converts cholesterol (specifically 7-dehydrocholesterol in the skin) into previtamin D3 — and separately, sunlight exposure is associated with higher HDL and lower LDL in population studies. Patients with minimal sun exposure reliably show elevated LDL in the absence of dietary changes. The body appears to use cutaneous cholesterol as a substrate for photoconversion; when sunlight is absent, that substrate accumulates. Before prescribing a statin for elevated LDL, asking about sun exposure is a clinically relevant question that is almost never posed.

A note on senior TSH ranges — and why they make no clinical sense

The suppressed TSH trap: over-medicated on paper, still hypothyroid in the body

A TSH of 0.5 mIU/L tells you one thing: the pituitary believes there is enough thyroid hormone circulating. It does not tell you whether the active thyroid hormone — T3 — is actually reaching the cells and doing its job. This distinction is the most commonly missed piece of thyroid management in older adults, and the failure to address it is clinical inertia with real consequences. Levothyroxine (Synthroid, generic) provides T4 — the storage form of thyroid hormone. T4 must be converted to T3, the active form, by deiodinase enzymes (primarily in the liver, gut, and kidney). This conversion is impaired by: chronic inflammation, elevated cortisol, selenium deficiency, gut dysfunction, certain medications (amiodarone, beta-blockers, corticosteroids), and aging itself. A senior on levothyroxine for years may have a TSH of 0.5 — looking "suppressed" or well-dosed on paper — while their Free T3 is low and every hypothyroid symptom persists. The TSH is suppressed by the T4 load; the cells are still starved of active hormone. The standard of care is to dose levothyroxine to a TSH within range — typically 0.4–4.5, or the wider senior range. If TSH is 0.5, the doctor sees "low-normal" or "slightly suppressed" and either leaves the dose unchanged or reduces it. Free T3 and Free T4 are rarely ordered. Reverse T3 — the inactive form that blocks T3 receptors and accumulates under stress and poor conversion — is almost never checked. The patient reports ongoing fatigue, brain fog, weight gain, constipation, hair loss, and cold intolerance. These are documented hypothyroid symptoms. They are attributed to age. The medication is not changed. Sometimes it is reduced, making the problem worse. Routinely ordered. Tells you pituitary signaling, not cellular function. A suppressed TSH does not mean the patient is well. Free T3 (rarely ordered) The active hormone. Low Free T3 with suppressed TSH = conversion problem. Patient is receiving T4 but not using it. Symptoms will persist regardless of TSH. Reverse T3 (almost never ordered) The inactive form. When rT3 is elevated, it occupies T3 receptors and blocks active hormone. A patient can have adequate T3 levels but be functionally hypothyroid because rT3 is filling the receptor sites. What to ask: "My TSH is low but I still have every hypothyroid symptom. Has my Free T3 been tested? Has my Reverse T3 been tested? Is T4-to-T3 conversion being evaluated — or are we only managing the TSH number?" A senior whose TSH is 0.5 and who still feels hypothyroid is not over-medicated. They may be under-converting. Those are two entirely different clinical situations requiring two entirely different responses — and they are almost never distinguished.

The test that would catch it early — and is almost never ordered

The Range Problem

• → Most lab "normal": ALT ≤ 40–56 U/L (varies by lab)
• → Prati et al. (2002, Annals of Internal Medicine ): After excluding individuals with metabolic risk factors, the true upper limit of normal for healthy adults is approximately 30 U/L for men, 19 U/L for women
• → A patient with ALT of 45 is told their liver enzymes are "normal" — but by a reference population that included people with NAFLD and medication burden
• → Significant liver pathology (early fibrosis, steatosis) can exist with ALT readings within the lab's "normal" range

Why This Matters

• → Statins are monitored with liver enzymes — but the reference range for "safe" may mask early statin hepatotoxicity
• → Multiple medications elevate liver enzymes within "normal" range — the damage accumulates below the threshold of concern
• → Acetaminophen (the #1 cause of acute liver failure in the US) can produce significant glutathione depletion with ALT still technically "normal"
• → A consistently elevated ALT of 38 in a woman — "normal" by most labs, but nearly double the true upper limit for healthy women — is a meaningful signal

The Age-Correction Problem

The muscle mass problem — and why frail elderly are systematically misread

Creatinine is produced by muscle tissue. The eGFR formula assumes a normal level of muscle mass for age and sex — but does not measure it. A frail 78-year-old woman who has lost significant muscle mass from years of inactivity, malnutrition, or chronic illness will produce very little creatinine. Her creatinine reads 0.68 — "normal." The formula calculates an eGFR of 74 — "normal kidney function." In reality her kidneys may be filtering poorly, but the low creatinine input makes the calculated output look fine. This is not a rare edge case: sarcopenia (age-related muscle loss) is nearly universal in the elderly and makes standard creatinine-based eGFR systematically unreliable in this population. Cystatin C is an alternative kidney marker not affected by muscle mass — produced by all nucleated cells at a constant rate, independent of age, sex, or muscle. It is a more accurate indicator of kidney function in elderly, frail, or very lean patients. It is rarely ordered. When it is ordered and compared to the creatinine-based eGFR, the gap frequently reveals that kidney function is worse than the standard panel suggested — or in some cases, better, catching patients who were over-staged due to high muscle mass.

What a CKD diagnosis enables — and what it restricts

The DEXA scan measures density — not bone quality, architecture, or living bone

What is actually driving the bone loss — and what the prescription conversation never reaches

Bone density is downstream of bone metabolism — and bone metabolism is affected by a set of modifiable inputs that are documented in the literature but almost never discussed at the time of a DEXA scan result and bisphosphonate prescription. Bone is a piezoelectric tissue — it generates electrical signals in response to mechanical stress, and those signals drive osteoblast (bone-building) activity. This is why weight-bearing exercise builds bone. Non-native EMF — from cell phones, cars (which act as Faraday cages concentrating ELF fields around the body), Wi-Fi, and medical imaging devices — activates voltage-gated calcium channels (VGCCs) in cell membranes throughout the body, including in bone cells. Dysregulated calcium signaling in osteoblasts and osteoclasts disrupts the remodeling cycle. The unprecedented saturation of EMF in modern environments — in every car, every room, every pocket — represents a calcium signaling disruption operating continuously at a scale no prior generation experienced. Caffeine increases urinary calcium excretion — each 6 mg of caffeine consumed is associated with approximately 1 mg of calcium lost in urine. At habitual high intakes (300–500 mg/day, common in coffee drinkers), cumulative calcium loss is meaningful over years. Caffeine also stimulates cortisol secretion; elevated cortisol directly inhibits osteoblast activity and increases osteoclast activity — the opposite of what you want for bone density. Population studies consistently show inverse associations between high caffeine intake and bone density, particularly in women with low dietary calcium. This is not mentioned in the DEXA result conversation. Ionizing radiation damages bone marrow and bone-forming cells. Patients with histories of radiation therapy — even to adjacent fields — often have locally impaired bone metabolism in the treated area. The cumulative CT scan burden in chronic patients represents significant ionizing radiation exposure over years. Iodinated contrast agents used in CT and angiography cause transient but repeated oxidative stress and, in patients with marginal kidney function, nephrotoxicity that secondarily affects calcium and phosphorus metabolism. DEXA itself uses low-dose X-ray — adding incrementally to cumulative radiation burden when ordered annually. Cavitations are areas of ischemic osteonecrosis in the jawbone — regions where blood supply has been compromised, bone has died, and the empty space (cavitation) is not visible on standard dental X-ray. They develop at sites of tooth extractions (especially wisdom teeth) where healing was incomplete, and are significantly more common in patients on bisphosphonates (MRONJ — medication-related osteonecrosis of the jaw), but also occur independent of drug use in patients with poor bone metabolism, high heavy metal burden, and compromised microcirculation. Biological dentists identify cavitations as a source of chronic systemic inflammation and a window into the quality of bone metabolism throughout the body — not just the jaw. A patient whose jawbone is forming cavitations is not building and maintaining bone correctly anywhere. What to ask before accepting a bisphosphonate prescription: "Has my calcium, magnesium, phosphorus, vitamin K2 status, protein intake, weight-bearing activity level, and cortisol been evaluated? Has anyone asked about my EMF environment, caffeine intake, or medication history? What is driving the bone loss — and has that been addressed? If I take this drug for five years and it keeps dead bone in my skeleton, what happens when I stop — and what is my risk of atypical fracture and jaw osteonecrosis?"

Statins → Diabetes

Statins are associated with a 10–12% increased risk of new-onset type 2 diabetes — a finding confirmed across multiple large trials and acknowledged in FDA labeling since 2012. The mechanism: statins reduce insulin secretion from pancreatic beta cells (which require the mevalonate pathway for normal function) and increase insulin resistance in muscle cells. A patient prescribed a statin for high cholesterol develops diabetes within 3–5 years. The diabetes is then treated with metformin, a GLP-1 agonist, or an SGLT-2 inhibitor. The statin is rarely reconsidered as a contributing cause.

Antihypertensives → Sexual Dysfunction → Antidepressants

Beta-blockers and thiazide diuretics — two of the most commonly prescribed antihypertensive classes — have sexual dysfunction as a documented, common side effect. Erectile dysfunction from antihypertensives is well established; reduced libido and anorgasmia in women is documented but less studied. The sexual dysfunction leads to depression, relationship strain, and quality of life decline. An antidepressant is often added — which itself commonly causes sexual dysfunction, weight gain, and emotional blunting. The original antihypertensive is rarely identified as the starting point.

SSRIs → Weight Gain → Metabolic Disease → Hypertension

Antidepressants — particularly SSRIs and especially paroxetine (Paxil) and mirtazapine — are associated with significant weight gain in long-term use. The weight gain drives insulin resistance, elevated fasting glucose, dyslipidemia, and elevated blood pressure. A patient who was normotensive and non-diabetic before beginning an antidepressant is, three to five years later, on a blood pressure medication and approaching a prediabetes diagnosis. Each new condition is treated as independent. The antidepressant sits at the origin of the cascade, rarely examined.

Proton Pump Inhibitors → Magnesium Deficiency → Hypertension + Arrhythmia

PPIs (omeprazole, esomeprazole, pantoprazole) suppress gastric acid required for magnesium absorption. Long-term PPI use causes hypomagnesemia — FDA warning issued in 2011. Magnesium is the body's natural calcium channel blocker and is required for vascular smooth muscle relaxation and cardiac electrical stability. Magnesium deficiency drives elevated blood pressure and cardiac arrhythmia — particularly atrial fibrillation. A patient on a PPI for acid reflux develops elevated blood pressure (treated with an antihypertensive) and atrial fibrillation (treated with an antiarrhythmic or anticoagulant). The PPI, still running in the background, is the origin. It is almost never stopped.

Bisphosphonates → Atypical Fractures → Joint Replacement → Surgical Complications

As described in the bone density section: bisphosphonates suppress osteoclast activity, accumulate dead bone in the skeleton, improve DEXA scores, and in long-term users produce atypical subtrochanteric femoral fractures — complete transverse breaks under minimal stress. These fractures frequently require surgical fixation or hip replacement. The hip replacement is performed in bone that has been pharmacologically altered for years — periprosthetic fracture rates are higher, osseointegration of implants is impaired, and the surgical complications are attributed to age and bone fragility rather than to the drug that altered the bone biology. The drug prescribed to prevent fractures contributed to the fracture. The surgery required to fix it carries its own complication profile. The trajectory from DEXA scan to operating table is a straight line that is almost never acknowledged as such.

Corticosteroids → Osteoporosis + Hyperglycemia + Adrenal Suppression

Corticosteroids (prednisone, dexamethasone, methylprednisolone) — prescribed for autoimmune conditions, inflammatory disease, asthma, and many other conditions — directly suppress osteoblast activity, driving bone loss significant enough to produce steroid-induced osteoporosis. They also elevate blood glucose (steroid hyperglycemia), often requiring insulin or oral diabetes medication during use. Long-term or repeated use suppresses the HPA axis, leading to adrenal insufficiency — a condition that then requires careful steroid taper, supplementation, and long-term monitoring. A patient who received corticosteroids for inflammatory bowel disease, asthma, or a rheumatologic condition may leave with osteoporosis, steroid-induced diabetes, and adrenal suppression — each of which generates its own prescription and monitoring cascade. The steroid is the common origin of all three.

The cascade is the business model

This is not anti-medicine. It is informed medicine.

The information on this page is not an argument against treating elevated blood pressure, high cholesterol, diabetes, or thyroid disease. These are real conditions with real consequences. It is an argument for understanding the context of the number you are given — how it was defined, when the definition changed, and whether the distance between your result and the threshold represents meaningful clinical risk or a recently moved line. Informed consent means understanding what "borderline" actually means — and making decisions with that full picture rather than responding to a number on a printout without its history.